The estimated Net Worth of Neil Yeston is at least $313 Mille dollars as of 13 December 2012. Neil Yeston owns over 5,000 units of MiMedx Inc stock worth over $30,950 and over the last 12 years he sold MDXG stock worth over $0. In addition, he makes $282,125 as Independent Director at MiMedx Inc.
Sign up
Neil Yeston MDXG stock SEC Form 4 insiders trading
Neil has made over 1 trades of the MiMedx Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of MDXG stock worth $17,600 on 13 December 2012.
The largest trade he's ever made was buying 5,000 units of MiMedx Inc stock on 13 December 2012 worth over $17,600. On average, Neil trades about 714 units every 0 days since 2012. As of 13 December 2012 he still owns at least 5,000 units of MiMedx Inc stock.
You can see the complete history of Neil Yeston stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Neil Yeston biography
Dr. Neil S. Yeston M.D. serves as Independent Director of the Company. Dr. Yeston is the Past President of the New England Surgical Society and currently serves as Active Senior Staff, Department of Surgery at Hartford Hospital. During his association with Hartford Hospital, Dr. Yeston previously served in various roles including Vice President of Academic Affairs, Director of Corporate Compliance, Vice President of Quality Management and Director of the Section on Critical Care Medicine, Department of Surgery. In addition, Dr. Yeston was responsible for the enterprise wide acquisition of all biomedical engineering technology. Dr. Yeston has formerly served as Professor of Surgery at the University of Connecticut and the Assistant Dean, Medical Education at the University of Connecticut School of Medicine. Prior to his associations with Hartford Hospital and the University of Connecticut, Dr. Yeston served in various positions with the Boston University Medical Center including the Vice Chairman of the Department of Surgery, Associate Professor of Anesthesiology, Director Progressive Care Unit, and Associate Professor of Surgery. Dr. Yeston has served on the Board since 2012 and was nominated as a director because of his in-depth understanding of healthcare issues from the perspective of the practitioner, academician, administrator and executive.
What is the salary of Neil Yeston?
As the Independent Director of MiMedx Inc, the total compensation of Neil Yeston at MiMedx Inc is $282,125. There are 9 executives at MiMedx Inc getting paid more, with Timothy Wright having the highest compensation of $5,069,350.
How old is Neil Yeston?
Neil Yeston is 77, he's been the Independent Director of MiMedx Inc since 2012. There are no older and 22 younger executives at MiMedx Inc.
What's Neil Yeston's mailing address?
Neil's mailing address filed with the SEC is C/O MIMEDX GROUP, INC., 1775 WEST OAK COMMONS COURT, NE, MARIETTA, GA, 30062.
Insiders trading at MiMedx Inc
Over the last 15 years, insiders at MiMedx Inc have traded over $15,165,698 worth of MiMedx Inc stock and bought 1,553,718 units worth $4,191,559 . The most active insiders traders include Fund Management Ltd.Okumus ..., Steve Gorlin e Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of $487,865. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth $162,029.
What does MiMedx Inc do?
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
What does MiMedx Inc's logo look like?
Complete history of Neil Yeston stock trades at MiMedx Inc
MiMedx Inc executives and stock owners
MiMedx Inc executives and other stock owners filed with the SEC include:
-
Timothy Wright,
Chief Executive Officer, Director -
Peter Carlson,
Chief Financial Officer -
Timothy R. Wright,
CEO & Director -
Dr. Robert Benjamin Stein M.D., Ph.D.,
Exec. VP of R&D -
Peter Martin Carlson CPA,
Chief Financial Officer -
William F. Hulse IV,
Gen. Counsel & Sec. -
Scott Turner,
Senior Vice President - Operations and Procurement -
Dr. Rohit Kashyap Ph.D.,
Exec. VP & Chief Commercial Officer -
Charles Evans,
Independent Director -
Neil Yeston,
Independent Director -
M. Kathleen Behrens Wilsey,
Independent Chairman of the Board -
James Bierman,
Independent Director -
K. Todd Newton,
Independent Director -
Charles Koob,
Director -
Jack Howarth,
Senior Vice President of Investor Relations -
Robert Stein,
Executive Vice President - Research and Development -
Rohit Kashyap,
Executive Vice President, Chief Commercial Officer -
Martin Sutter,
Independent Director -
William Hawkins,
Independent Director -
William Phelan,
Senior Vice President, Chief Accounting Officer -
William Hulse,
General Counsel, Secretary -
Mark Graves,
Chief Compliance Officer -
Scott M. Turner,
Sr. VP of Operations & Procurement -
Stan Micek,
Sr. VP of Bus. Devel. & Portfolio Management -
Dr. David H. Mason Jr.,
Chief Medical Officer -
Hilary Dixon,
VP of Investor Relations & Corp. Communications -
John J. Howarth,
Sr. VP of Investor Relations -
William L. Phelan,
Sr. VP & Chief Accounting Officer -
Larry W Papasan,
Director -
William Charles Taylor,
President and COO -
Michael J. Senken,
Chief Financial Officer -
Joseph G Bleser,
Director -
Parker H Petit,
Chairman & CEO -
J Terry Dewberry,
Director -
Bruce Hack,
Director -
Luis A Aguilar,
Director -
Fund 2 Holding Company, L.P...,
-
Mark Landy,
EVP & Chief Strategy Officer -
Fund Management Ltd.Okumus ...,
-
Edward Borkowski,
EVP & Interim CFO -
Tiffany Olson,
Director -
Kurt M Eichler,
Director -
Thomas J Koob,
Chief Scientific Officer -
Roberta L Mccaw,
General Counsel and Secretary -
Steve Gorlin,
Director -
Rebeccah Covert Brown,
-
Michael J Giuliani,
Director -
Cato T Laurencin,
Director -
M Kathleen Behrens,
Director -
Richard Barry,
Director -
Joseph H Capper,
Chief Executive Officer -
Phyllis Gardner,
Director -
Ricci S Whitlow,
Chief Operating Officer -
Todd Newton,
Director -
Rice Doug,
Chief Financial Officer -
Dorothy E Puhy,
Director